PUT - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 01:43:45 2024-07-05 pm EDT | ||
| 3.59 EUR | -10.25% |
|
| Current month | -0.83% | ||
| 1 month | +22.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 3.59 | -10.25% |
| 24-07-04 | 4 | -3.85% |
| 24-07-03 | 4.16 | +7.49% |
| 24-07-02 | 3.87 | -8.08% |
| 24-07-01 | 4.21 | +16.30% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 01:43 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM75SD |
| ISIN | DE000VM75SD4 |
| Date issued | 2024-01-08 |
| Strike | 512.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.44 € |
|---|---|
| Lowest since issue | 2.53 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
